Current Report Filing (8-k)
December 14 2018 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 12,
2018
CORVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37719
|
|
46-4670809
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
863 Mitten Road, Suite 102
Burlingame, CA 94010
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650)
900-4520
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933(17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company [ X ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ X ]
Item 5.02
|
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
2019 Annual Salaries and Stock Option Awards
On December 12, 2018, the Board of Directors
(the “Board”) of Corvus Pharmaceuticals, Inc. (“Corvus” or the “Company”), approved, on recommendation
of the Compensation Committee of the Board, increases to the annual base salaries and stock option awards for the Company’s
Chief Executive Officer, Chief Financial Officer and Chief Business Officer. The stock option awards to each of the executive officers
will be granted effective as of the close of business on December 12, 2018 with an exercise price equal to the closing price of
the Company’s common stock as reported on The Nasdaq Global Market on the date of grant. The awards will be made pursuant
to the Company’s 2016 Equity Incentive Award Plan and will vest in equal monthly installments over 48 months, subject to
continued service as of each vesting date.
The following table sets forth the 2019 annual
base salary and number of shares underlying the stock option awards for each of the named executive officers and principal financial
officer:
Name and Principal Position
|
|
2019 Base Salary
($)
|
|
Stock Option Award
(shares)
|
Richard A. Miller, M.D.
|
|
$
|
300,000
|
|
|
|
250,000
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
Leiv Lea
|
|
$
|
350,000
|
|
|
|
100,000
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
|
Daniel W. Hunt, J.D.
|
|
$
|
386,250
|
|
|
|
50,000
|
|
Senior Vice President and Chief Business Officer
|
|
|
|
|
|
|
|
|
Departure of Director
On December 12, 2018, Peter Moldt Ph.D. notified the Company of
his intention to resign from the Board as well as each of the audit committee and nominating and corporate governance committee
in the first half of 2019. Dr. Moldt’s resignation is not due to any disagreement with the Company, the Board or management
of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CORVUS PHARMACEUTICALS, INC.
|
|
|
|
Date: December 14, 2018
|
|
By:
|
/s/ Leiv Lea
|
|
|
|
Leiv Lea
|
|
|
|
Chief Financial Officer
|
|
|
|
|
|
|
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Sep 2023 to Sep 2024